Pancreatic cancer (PC) carries a poor prognosis, partially due to lack of early diagnosis. To address this unmet need, the potential of magnetic resonance molecular imaging of extradomain B fibronectin with an oligopeptide targeted MRI contrast agent was assessed in mouse models of PC. Four PC cell lines were assayed for EDB-FN expression in vitro and found to overexpress EDB-FN. Analysis of ZD2 binding and contrast enhanced MRI demonstrated over two-fold improvement in CNR compared to non-targeted gadoteridol, with little non-specific binding. Histological analysis revealed the expression of EDB-FN in the tumor microenvironment and confirmed the features observed on MRI
This abstract and the presentation materials are available to members only; a login is required.